人免疫球蛋白联合阿昔洛韦治疗病毒性脑膜炎的临床效果分析

Clinical Effect Analysis of Human Immunoglobulin and Acyclovir in Treatment of Viral Meningitis

目的:探讨人免疫球蛋白联合阿昔洛韦治疗病毒性脑膜炎的临床效果。方法:选取2020年3月—2023年2月无锡市第八人民医院收治的80例病毒性脑膜炎患者作为研究对象,采用随机数字表法分为对照组与研究组,各40例。对照组采用阿昔洛韦治疗,研究组在对照组基础上采用人免疫球蛋白治疗。比较两组临床疗效、症状恢复时间、不良反应发生情况。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P=0.048)。研究组头痛、意识障碍、高热恢复时间短于对照组,差异有统计学意义(P<0.001)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:人免疫球蛋白联合阿昔洛韦治疗病毒性脑膜炎的临床效果较好,能够促进患者症状恢复,且不会增加不良反应,安全性较高。

Objective:To explore the clinical effect of human immunoglobulin and acyclovir in the treatment of viral meningitis.Methods:A total of 80 patients with viral meningitis admitted to Wuxi Eighth People's Hospital from March 2020 to February 2023 were selected as the study subjects.They were divided into control group and study group by random number table method,with 40 cases in each group.The control group received acyclovir treatment,and the study group received human immunoglobulin treatment on the basis of control group.The clinical efficacy,the symptom recovery time,and the occurrence of adverse reactions of the two groups were compared.Results:The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P=0.048).The recovery time of headache,consciousness disorders and hyperpyrexia in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of human immunoglobulin and acyclovir has good clinical effects in treatment of viral meningitis,and can promote the recovery of symptoms without increasing adverse reactions,and have a high safety profile.